XL 184

• Supplier: Tocris Bioscience
• Catalog: 5510
• Prices: $199.00, $825.00
• Sizes: 10 mg, 50 mg
• Function Type: Inhibitor
• Cas Number: 849217-68-1
• Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
• Formula: C28H24FN3O5
• Molecular Weight: 501.51
• Purity: >98 %
• Description: Potent VEGFR inhibitor (IC 50 = 0.035 nM); also inhibits c-Met, KIT, RET, FLT4, AXL, FLT3, FLT1 and Tie2 (IC 50 values are 1.3, 4.6, 5.2, 6, 7, 11.3, 12 and 14.3 nM, respectively). Induces intratumoral hypoxia and apoptosis. Reduces tumor invasion and metastasis in vivo . Antiangiogenic.

Product References

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses - Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Mol Cancer Ther. 2011 Dec;10(12):2298-308.

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet - VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet

You WK, Sennino B, Williamson CW, Falcon B, Hashizume H, Yao LC, Aftab DT, McDonald DM. Cancer Res. 2011 Jul 15;71(14):4758-68.